Scancell Hldgs Plc (SCLP) - Cash Flow Conversion Efficiency

Latest as of October 2025: 0.846x

Based on the latest financial reports, Scancell Hldgs Plc (SCLP) has a cash flow conversion efficiency ratio of 0.846x as of October 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-7.08 Million ≈ $-861.55 USD) by net assets (GBX-8.37 Million ≈ $-1.02K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Scancell Hldgs Plc (SCLP) total market value for the company's overall valuation and market capitalisation.

Scancell Hldgs Plc - Cash Flow Conversion Efficiency Trend (2009–2025)

This chart illustrates how Scancell Hldgs Plc's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Scancell Hldgs Plc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Scancell Hldgs Plc ranked by their cash flow conversion efficiency. Explore Scancell Hldgs Plc cash flow quality index to measure how well operating cash flow supports reported net income.

Company Cash Flow Conversion Efficiency
GLOBAL HELIUM CORP.
F:5P0
N/A
Sagalio Energy Ltd
AU:SAN
-0.002x
ARC MINERALS LTD
F:DFYA
N/A
FRNT Financial Inc
V:FRNT
-0.111x
Baring Emerging Europe Plc
LSE:BEMO
0.014x
Value Management & Research AG
F:VMR1
0.239x
Diamcor Mining
V:DMI
-0.005x
DCM Financial Services Limited
NSE:DCMFINSERV
0.000x

Annual Cash Flow Conversion Efficiency for Scancell Hldgs Plc (2009–2025)

The table below shows the annual cash flow conversion efficiency of Scancell Hldgs Plc from 2009 to 2025. View current stock price of Scancell Hldgs Plc for real-time trading data and today's change.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-04-30 GBX-3.83 Million
≈ $-466.61
GBX-6.11 Million
≈ $-742.92
1.592x -64.36%
2024-04-30 GBX-3.50 Million
≈ $-426.46
GBX-15.66 Million
≈ $-1.91K
4.468x +242.12%
2023-04-30 GBX-6.23 Million
≈ $-758.38
GBX-8.14 Million
≈ $-990.40
1.306x +426.11%
2022-04-30 GBX19.48 Million
≈ $2.37K
GBX-7.80 Million
≈ $-949.40
-0.400x +60.75%
2021-04-30 GBX7.65 Million
≈ $930.54
GBX-7.80 Million
≈ $-949.40
-1.020x -35.45%
2020-04-30 GBX9.34 Million
≈ $1.14K
GBX-7.03 Million
≈ $-855.71
-0.753x -0.21%
2019-04-30 GBX9.34 Million
≈ $1.14K
GBX-7.02 Million
≈ $-853.88
-0.752x -157.92%
2018-04-30 GBX13.94 Million
≈ $1.70K
GBX-4.06 Million
≈ $-494.32
-0.291x +50.77%
2017-04-30 GBX6.50 Million
≈ $790.78
GBX-3.85 Million
≈ $-468.13
-0.592x -153.79%
2016-04-30 GBX9.99 Million
≈ $1.22K
GBX-2.33 Million
≈ $-283.58
-0.233x +40.30%
2015-04-30 GBX6.75 Million
≈ $821.77
GBX-2.64 Million
≈ $-321.06
-0.391x -69.41%
2014-04-30 GBX9.08 Million
≈ $1.10K
GBX-2.09 Million
≈ $-254.70
-0.231x +41.23%
2013-04-30 GBX5.09 Million
≈ $619.57
GBX-2.00 Million
≈ $-243.14
-0.392x -418.26%
2012-04-30 GBX6.97 Million
≈ $848.21
GBX859.62K
≈ $104.59
0.123x +132.17%
2011-04-30 GBX4.64 Million
≈ $564.07
GBX-1.78 Million
≈ $-216.21
-0.383x -76.43%
2010-04-30 GBX6.05 Million
≈ $735.87
GBX-1.31 Million
≈ $-159.88
-0.217x -7.79%
2009-04-30 GBX5.25 Million
≈ $639.26
GBX-1.06 Million
≈ $-128.85
-0.202x --

About Scancell Hldgs Plc

LSE:SCLP UK Biotechnology
Market Cap
$1.22 Million
GBX10.07 Billion GBX
Market Cap Rank
#30565 Global
#779 in UK
Share Price
GBX9.70
Change (1 day)
-1.02%
52-Week Range
GBX9.20 - GBX26.50
All Time High
GBX27.50
About

Scancell Holdings plc, a clinical stage biopharmaceutical company, discovers and develops of immunotherapies for the treatment of cancer in the United Kingdom. Its product candidates include SCIB1/iSCIB1+ that is in Phase II for the treatment of melanoma; and SC134, an antibody for the treatment of small cell lung cancer. It also develops Modi-1, an active peptide immunotherapy that is in phase I… Read more